PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1
Authors:
- 25 May 2019
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 145 (7) , 1785-1794
Abstract
Purpose To investigate the associations between programmed cell death ligand-1 (PD-L1) on tumor cells (TCs) or PD-L1 on tumor-infiltrating immune cells (TIICs) and the microsatellite instability (MSI) status in colorectal cancer (CRC). Methods In total, 238 CRC patients were enrolled. PD-L1 expression and MSI status were studied by immunohistochemical staining and polymerase chain reaction. The χ2 test was used to compare characteristics. The Kaplan–Meier method was used for survival analysis. Cox proportional hazards models were used to determine the prognostic influence of clinicopathological factors. Results Eighteen patients (7.6%) were had MSI-high (MSI-H) CRC. The number of patients with PD-L1 expression on TCs, stromal TIICs and intraepithelial TIICs was 13 (5.5%), 64 (26.9%) and 45 (18.9%), respectively. The MSI-H phenotype was significantly associated with younger age, right sidedness, mucinous component, high grade, stromal TIICs expressing PD-L1 (P = 0.042) and intraepithelial TIICs expressing PD-L1 (P < 0.001), but not TCs expressing PD-L1. PD-L1-expressing TCs were an independent marker of poor prognosis [hazard ratio (HR) = 3.387, P = 0.003], and PD-L1-expressing stromal TIICs were an independent marker of good prognosis (HR = 0.551, P < 0.001). Conclusions PD-L1-expressing TCs were a marker of poor prognosis; in contrast, PD-L1-expressing TIICs were a marker of good prognosis. The MSI-H phenotype was associated with the presence of PD-L1-expressing TIICs, but not of PD-L1-expressing TCs.Keywords
Funding Information
- Taiwan Clinical Oncology Research Foundation
- Ministry of Science and Technology, Taiwan (MOHW107-TDU-B-211-114019)
- Taipei Veterans General Hospital (107DHA0100381, 108DHA0100103)
- Yen Tjing Ling Medical Foundation (CI-108-19)
This publication has 36 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenNew England Journal of Medicine, 2018
- TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomasOncoImmunology, 2018
- PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistryJournal of Clinical Pathology, 2017
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaCancer Immunology Research, 2015
- First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405Current Treatment Options in Oncology, 2015
- Improved Detection of Microsatellite Instability in Early Colorectal LesionsPLOS ONE, 2015
- Colorectal cancerThe Lancet, 2014
- Clinical impact of programmed cell death ligand 1 expression in colorectal cancerEuropean Journal of Cancer, 2013
- Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk FactorsClinics in Colon and Rectal Surgery, 2009
- Restoring function in exhausted CD8 T cells during chronic viral infectionNature, 2005